Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

VYNE THERAPEUTICS INC.

(VYNE)
  Report
Delayed Nasdaq  -  04:00:00 2023-05-26 pm EDT
6.600 USD   -6.52%
05/18VYNE Therapeutics to Attend BIO International Convention
AQ
05/12Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating
MT
05/11VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $11 from $14, Keeps Buy Rating

05/07/2021 | 01:37pm EDT


ę MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
05/18VYNE Therapeutics to Attend BIO International Convention
AQ
05/12Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Ov..
MT
05/11VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
05/11Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $99,000
MT
05/11VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Up..
AQ
05/03University Of Dundee : Spinout agrees potential $50 million deal
AQ
05/01Vyne Therapeutics Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclos..
AQ
05/01VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best..
AQ
05/01VYNE Therapeutics Inc. Announces Selection of Development Candidate VYN202, a Potential..
CI
04/19VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201..
AQ
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2023 0,25 M - -
Net income 2023 -30,6 M - -
Net Debt 2023 - - -
P/E ratio 2023 -1,18x
Yield 2023 -
Capitalization 21,6 M 21,6 M -
Capi. / Sales 2023 86,4x
Capi. / Sales 2024 -
Nbr of Employees 12
Free-Float 96,9%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 6,60 $
Average target price 13,67 $
Spread / Average Target 107%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.144.44%22
JOHNSON & JOHNSON-12.62%431 789
ELI LILLY AND COMPANY16.39%404 191
NOVO NORDISK A/S21.28%366 763
MERCK & CO., INC.0.11%281 833
ROCHE HOLDING AG0.07%259 001
-40% off: Our subscriptions help you unlock hidden opportunities!
Subscribe
fermer